Skip to main content
ACIU logo

ACIU

AC Immune SA
$2.18 -0.18 (-7.63%) At close · Jul 16
Market Cap
$220.85M
Shares
101,773,573

Price & Indicators

20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$2.18 Open$2.35 Day$2.16–2.35 52W$2.00–4.00 Avg vol 30d277K Short int3.4M · 3.3% float · 13.0d Short vol74% DataJan 2020–Jul 2026
Up next
FQ3-26 quarter ends
~Sep 30, 2026 Est
Equibles Rating blended score · not investment advice
Overall
Strong Sell
SellHoldBuy
Technical Strong Sell Momentum Very Weak Sentiment Neutral Fundamentals Limited Quant / Vol Very High
Market backdrop VIX 16.7 · calm Equity put/call 0.67
Technical
price trend
Strong Sell
50 / 200-day cross No cross
Price vs 200-day avg −27%
below
Price vs 50-day avg −15%
below
RSI (14) 36
neutral
MACD trend Negative
52-week position 9%
near low
Momentum
relative strength
Very Weak
1-month return −8%
trailing
6-month return −40%
trailing
YTD return −31%
this year
Relative strength −49%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $3 › 200d $3 — 200d above 50d
Institutional flow Flat
2 of 47 funds reported for Jun 30 · net 0 sh shares
Insider flow Distributing
Net -$27.9K over 90 days · 100% sells
Short interest Falling
3.32% of float · ▼ -4.0% MoM · 13.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
47 holders — near 3-yr high, broad support
Squeeze score 59
elevated · 0–100
Fundamentals
Limited
Not enough data for a confident read.
Quant / Vol
risk profile
Very High
Volatility 78%
annualized · 1-yr
Max drawdown −47%
past year
ATR 6.6%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Strong Sell
4 · 2 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−27% Bearish
Price vs 50-day avg
−15% Bearish
RSI (14)
36 Neutral
MACD trend
Negative Bearish
52-week position
9% Bearish
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $3 › 200d $3 — 200d above 50d
Institutional flow Flat
2 of 47 funds reported for Jun 30 · net 0 sh shares
Insider flow Distributing
Net -$27.9K over 90 days · 100% sells
Short interest Falling
3.32% of float · ▼ -4.0% MoM · 13.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
47 holders — near 3-yr high, broad support
Price context
position in its 52-week range
52-wk low $2 Now $2 · 9% 52-wk high $4
vs 200-day avg -27% vs 50-day avg -15%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
ACIU
AC Immune SA
this stock
$220.85M -30.6% 3.3%
ONC
BeOne Medicines Ltd.
$458.76B +4.5% +22179.2% 933.6 0.1%
VRTX
Vertex Pharmaceuticals Inc / Ma
$123.36B +7.2% +46.2% 28.8 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
$71.18B -11.9% +20.8% 16.6 3.3%
ARGX
Argenx SE
$53.68B +2.0% 2.3%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders
Holders
47
% held
25.0%
Reported
2 of 47
Top holder
BVF INC/IL
Held Float
View
Held by Funds
Fund positions
8
View
Short & Settlement
Short Interest Falling
Shares short
3.4M
Days to cover
13.0d
Change
-139.3K sh
View
Short Volume
Short vol %
74%
As of
Jul 16, 2026
Short Total
View
Fails to Deliver
FTD shares
11.9K
Value
$30.3K
As of
Jun 29, 2026
View
Off-Exchange
Off-exchange %
53.5%
Week of
May 4, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net selling
Net (90d)
-$27.9K
Buyers / Sellers
0 / 1
Buyers Sellers
View
Filings
SEC Filings
Latest
6-K
Filed
Jun 30, 2026
This year
12
View
Proposed Sales
Value
$56.0K
Shares
20.0K
Filed
May 15, 2026
View

Performance

5D 20D 120D MTD YTD
ACIU -16.2% -8.0% -39.9% -8.4% -30.6%
SPY -0.1% +0.1% +9.0% +0.5% +10.1%
vs SPY -16.0% -8.1% -48.9% -8.9% -40.7%
Key facts CIK 1651625 CUSIP H00263105 13F (30d) 2 filings 2 filers Visit website Investor relations